J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
After committing billions of dollars to a new hepatitis C cocktail that had the potential to compete with the already deeply entrenched rivals on the market, J&J is calling it quits.
Drawn to hepatitis C at a time when the field was undergoing a dramatic shift in coming up with a painless resolution of the disease, that work is now done. Gilead led the way in curing hep C, followed by a slew of competitors who have been whittling down the cost as they scrambled to find new and better ways to do the job ever quicker.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.